LGVN News and Press, Longeveron Inc. From 05/14/21

Longeveron Inc. (LGVN) Q1 2021 Earnings Conference Call May 14, 2021 8:30 AM ET Company Participants Brendan Payne – Stern Investor Relations Geoff Green – Chief Executive Officer James Clavijo – Chief Financial Officer Joshua Hare – Co-Founder, Chief Scientific Of...

Longeveron (LGVN): Q1 GAAP EPS of -$0.18.Revenue of $0.38M (-77.8% Y/Y)Press Release For further details see: Longeveron reports Q1 results

MIAMI, May 14, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today provided a business update regarding a number of ongoing ...

MIAMI, May 11, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its first qua...

Longeveron recently announced positive results from a Phase 1 study of Lomecel-B in Alzheimer's disease, and the completion of two Phase 2 clinical trials evaluating the safety and efficacy of Lomecel-B infusion in Aging Frailty subjects. Top-line results from the Aging Frailty ...

MIAMI, April 27, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announces it has been selected to present at the 2021 World ...

Longeveron (LGVN) announces the completion of the company’s Phase I/II clinical study of the use of Lomecel-B to improve immune response to influenza vaccine in subjects with Aging Frailty.The company expects to announce top-line trial results in the third-quarter of 2021.In the P...

Longeveron (LGVN) soars 26% premarket in reaction to the announcement of final results of its Phase I clinical study evaluating the safety and efficacy of intravenous administration of Lomecel-B in subjects with mild Alzheimer’s disease ((AD)). Key findings from new and previ...

Study meets primary safety endpoint; positive secondary efficacy assessments support potential benefit from Lomecel-B Decline in cognitive function slower in patients who received low-dose Lomecel-B as compared with placebo Quality of life metrics improved with Lomecel-B c...

New York, New York--(Newsfile Corp. - April 12, 2021) - Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, was recently the focus of coverage by leading fina...